Class III cardiovascular and structural heart devices, run through European sites with VARC-3 endpoints, imaging core lab, independent adjudication, PMCF and CER.
Chief Operating Officer & Head of Cardiovascular
in cardiac surgery & cardiovascular device evaluation
Head of Cardiovascular Clinical Operations · DACH
ReCor
in international clinical research (cardiovascular & interventional)
Chief Data Officer · Biometrics & Data Systems
in clinical data management, EDC & biometrics systems
Senior Clinical Data Manager · Cardiovascular
in cardiovascular clinical data management
Lead Clinical Project Manager · Cardiovascular programs (France & UK)
in clinical research & medical device studies
Our clinical team on site with the manufacturers who trust Eclevar to run their cardiovascular and structural heart evidence.
Class III cardiac submissions rarely fail because a document is completely missing. They fail because the evidence chain is internally inconsistent: the intended purpose is broader than the studied population, the label claims durability beyond the available follow-up, or the PMCF plan does not target the uncertainties left by the pre-market program.
Other recurring inconsistencies include:
Under the currently consolidated EU MDR framework, clinical evaluation must be planned, conducted and documented across the device lifecycle. The framework for a Class III cardiac implant combines:
For implantable and Class III devices, clinical investigations are generally expected under Article 61, subject to defined exceptions whose applicability must be documented. This page explains how these texts combine, what deliverables they trigger and what risks emerge; it does not reproduce the articles in full.
The pathway is driven by questions, not documents: what evidence already exists, is it device-specific, does it cover each indication and claim, does the studied population match the target population, does the follow-up match the risks, are design variations covered, and are residual uncertainties assigned to PMCF?
For Class III implantable cardiac devices, clinical investigations are generally central to the pre-market evidence package, unless a documented Article 61 route or applicable exception can be justified. Article 61(4) provides for clinical investigations for implantable and Class III devices, while the following paragraphs establish specific exceptions, including for certain modifications or well-established technologies.
Clinical-investigation exceptions (Article 61), CECP exemptions (Article 54), well-established-technology considerations and common-specification applicability are four distinct concepts. They are close, but not interchangeable, and each must be assessed and documented on its own terms.
The central question a reviewer asks: can the evidence be traced to the submitted device?
European execution
Country selection drives cardiovascular center density, device adoption, registry access, imaging readiness, follow-up reliability, contracting timelines and cost per patient.
Registry access and data governance vary by Nordic country and are assessed individually during feasibility.
Every element of the intended purpose maps to a reviewer question, and every claim must trace to the evidence that supports it.
| Element | The reviewer's question |
|---|---|
| Intended purpose | Was the device studied in this exact use? |
| Indication | Do the pathology and risk level match? |
| Population | Are age, anatomy, comorbidities and contraindications covered? |
| User | Do the operators reflect intended use? |
| Setting | Do the studied centers reflect future centers? |
| Claim | Is each claim supported by an endpoint? |
| Follow-up | Does the duration support the claim? |
| Claim or use element | Evidence source | Population covered | Device generation | Follow-up | Residual gap |
|---|---|---|---|---|---|
| Procedural success | Clinical investigation | Target population | Submitted generation | 30 days | None |
| Reduced reintervention | Literature + PMCF | Partial | Predecessor | 2 years | Long-term confirmation |
| Durability | PMCF | Limited | Submitted generation | 1 year | 5-year follow-up |
A claim is only as strong as its traceability to the studied population, endpoint, device generation and follow-up period.
For complex cardiac implants, equivalence is often hard to defend given technical, biological, clinical, generation, material, design, delivery-system, population and procedural differences. The assessment must address technical, biological and clinical characteristics, access to the equivalent device's data, the differences and residual uncertainty, and the impact on claims and PMCF.
One of the most common and most decisive gaps: proving which generation the evidence supports. The traceability chain runs from investigated model to submitted model, through design, material, delivery-system, manufacturing and software changes, variant coverage, clinical-impact assessment and residual uncertainty.
| Modification | May affect | Expected evidence |
|---|---|---|
| Frame design | Positioning, radial force, conduction | Bench + clinical bridge |
| Valve material | Durability, thrombosis | Preclinical + clinical follow-up |
| Delivery system | Access and procedural safety | Usability / procedural evidence |
| Sizing range | Anatomy and population | Variant coverage |
| Implantation technique | Learning curve and outcomes | Training / proctoring data |
From site echo and CT to core lab reads, DICOM pseudonymisation and endpoint adjudication, we keep a single controlled pipeline, so the same clinical event never exists in three inconsistent forms.
From the MDR angle, the design is judged on whether it supports the intended claims: is the population aligned with the indication, the comparator justified, the endpoints clinically meaningful, the sample size defensible, the operators and centers representative, the imaging standardized, the adjudication independent, and the follow-up proportionate to the risk?
The regulatory logic, not the endpoint definitions: an endpoint is sufficient when it is linked to the intended claim, uses a validated or consensus framework, measures a clinically meaningful outcome, is adjudicated where needed, has an aligned analysis method, a justified follow-up window, and reports composite components separately.
Evidence reliability depends on acquisition standards, qualified and appropriately independent or blinded readers where required by the study design, a core-lab charter, imaging completeness, a CEC charter, source-document requirements, blinded adjudication, discrepancy management and database reconciliation.
The CER is where the whole clinical argument is consolidated: device and intended purpose, clinical background and state of the art, clinical development history, appraisal of pre-market data, literature evidence, equivalence assessment, PMS and PMCF evidence, benefit-risk determination, residual uncertainties, and conclusions by indication and claim.
Each document in the clinical file answers one clinical question, and the answers must be consistent across the file.
| Document | The clinical question |
|---|---|
| Risk management file | Which clinical risks remain open? |
| CIP | Which risks are tested pre-market? |
| CER | Does the clinical benefit outweigh the risks? |
| PMS plan | Which signals will be monitored? |
| PMCF plan | Which uncertainties will be actively studied? |
| PSUR | Does the benefit-risk remain acceptable? |
| Labeling | Do claims and warnings reflect the data? |
Frequent gap: the CER concludes favourably, but the PMCF or risk file still show uncertainties that are not integrated into the conclusion.
For cardiac implants, PMCF must be tied to the residual risks and the limits of the pre-market program: long-term durability, structural deterioration, thrombosis, reintervention, late neurological events, device deficiencies, rare complications, broader real-world populations, operator variability and indication expansion.
Class III implantable devices fall within the scope of Article 54, subject to the applicable exemptions. The consultation is embedded in the Notified Body's conformity-assessment process: the Notified Body, not the manufacturer, transmits its assessment to the relevant expert panel where applicable.
The main exemptions currently described include: renewal of a device already certified under MDR; modification of a device already marketed by the same manufacturer for the same intended purpose where the modification does not adversely affect the benefit-risk; and the existence of common specifications applicable to the clinical evaluation of the device type.
These questions support the assessment. Meeting one of them does not, by itself, establish an exemption.
| Question | Evidence needed |
|---|---|
| Is the device already MDR-certified? | Certificate and scope |
| Is it a modification of an existing device? | Change assessment |
| Same intended purpose? | Intended-purpose comparison |
| Benefit-risk unchanged? | Technical and clinical justification |
| Common specification available? | Applicability assessment |
The review logic a reviewer applies, presented generically and not as any specific body's checklist: Is the intended purpose clinically supported? Is the evidence device-specific? Is the study design appropriate? Are endpoints relevant and adjudicated? Is follow-up sufficient? Is equivalence defensible? Are all variants covered? Are changes traceable? Is PMCF proportionate? Are CER, RMF, PMS and labeling consistent? Is the benefit-risk conclusion justified?
The deficiencies below recur across Class III cardiac reviews because they attack the traceability of the evidence chain, not the completeness of any single document.
| Evidence gap | Why it blocks review | Review risk | Remediation effort |
|---|---|---|---|
| CER / RMF inconsistency | Inconsistent benefit-risk | High review risk | Medium |
| Unsupported equivalence | Excessive reliance on another device | High review risk | High |
| Follow-up too short | Durability claim unsupported | High review risk | High |
| Intended purpose broader than data | Unsupported extrapolation | High review risk | Medium |
| Incomplete variant coverage | Submitted device not covered | High review risk | Medium |
| PMCF not linked to gaps | Uncertainties not addressed | High review risk | Medium |
| Literature-only conclusion for a novel or modified implant | Device-specific evidence may be insufficient | High review risk | High |
| Population mismatch | Invalid generalisation | Moderate review risk | Medium |
| Weak endpoint rationale | Performance or benefit not demonstrated | Moderate review risk | Medium |
| Inadequate adjudication for critical endpoints | Endpoint classification may be inconsistent | Moderate review risk | Medium |
| Unjustified comparator | Clinical benefit hard to interpret | Moderate review risk | Medium |
| Device changes poorly traced | Evidence-generation mismatch | Moderate review risk | Limited |
When a Notified Body deficiency lands, the first task is not to write a response. It is to classify the underlying evidence problem and determine whether the gap is analytical or evidentiary.
Heart Team coordination, high-volume structural heart centers, proctoring logistics and monitoring, with VARC-3 endpoints and reimbursement-grade evidence built in from the protocol onwards.
Eclevar combines cardiac clinical expertise with former Notified Body review experience to assess the evidence package as a reviewer will see it: indication by indication, claim by claim and device generation by device generation.
| Engagement | Device ? challenge ? intervention ? deliverable |
|---|---|
| Structural heart CER remediation | Class III implant ? inconsistent indication and generation coverage ? claim-by-claim evidence remapping and CER restructuring ? revised CER, gap matrix and PMCF recommendations. |
| Coronary implant deficiency response | Coronary implant ? Notified Body concerns on device-specific evidence and follow-up ? literature reappraisal, statistical review and integrated deficiency strategy ? coordinated CER and response package. |
| Device-generation traceability | Modified cardiac implant ? predecessor evidence not fully bridged to submitted generation ? design-change and clinical-impact mapping ? generation traceability matrix and evidence-bridge plan. |
Related Eclevar pages across the cardiovascular and structural heart program, from clinical strategy and device evidence to core lab, PMCF and country delivery.
Regulation (EU) 2017/745 (MDR), currently consolidated version, in particular Article 54, Article 61, Annex XIV (Parts A and B), Annex XV, Annex IX and Annex I. See the official consolidated text on EUR-Lex.
Get a reviewer's-eye assessment of your clinical evidence, indication by indication, claim by claim, generation by generation, with the gaps that would block Notified Body review identified before submission.
